OBERON - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
September 23, 2022
End Date
August 29, 2027
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
September 23, 2022
End Date
August 29, 2027